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Abstract
Background: The emergence and rapid spread of the 2009 H1N1 pandemic influenza A virus (H1N1pdm) in humans
highlights the importance of enhancing the capability of existing influenza surveillance systems with tools for rapid
identification of emerging and re-emerging viruses. One of the new approaches is the RT-PCR electrospray ionization mass
spectrometry (RT-PCR/ESI-MS) technology, which is based on analysis of base composition (BC) of RT-PCR amplicons from
influenza ‘‘core’’ genes. Combination of the BC signatures represents a ‘‘genomic print’’ of an influenza A virus.
Methodology/Principal Findings: Here, 757 samples collected between 2006 and 2009 were tested, including 302 seasonal
H1N1, 171 H3N2, 7 swine triple reassortants, and 277 H1N1pdm viruses. Of the 277 H1N1pdm samples, 209 were clinical
specimens (throat, nasal and nasopharyngeal swabs, nasal washes, blood and sputum). BC signatures for the clinical
specimen from one of the first cases of the 2009 pandemic, A/California/04/2009, confirmed it as an unusual, previously
unrecognized influenza A virus, with ‘‘core’’ genes related to viruses of avian, human and swine origins. Subsequent analysis
of additional 276 H1N1pdm samples revealed that they shared the genomic print of A/California/04/2009, which differed
from those of North American swine triple reassortant viruses, seasonal H1N1 and H3N2 and other viruses tested. Moreover,
this assay allowed distinction between ‘‘core’’ genes of co-circulating groups of seasonal H1N1, such as clades 2B, 2C, and
their reassortants with dual antiviral resistance to adamantanes and oseltamivir.
Conclusions/Significance: The RT-PCR/ESI-MS assay is a broad range influenza identification tool that can be used directly
on clinical specimens for rapid and accurate detection of influenza virus genes. The assay differentiates the H1N1pdm from
seasonal and other nonhuman hosts viruses. Although not a diagnostic tool, this assay demonstrates its usefulness and
robustness in influenza virus surveillance and detection of novel and unusual viruses with previously unseen genomic
prints.
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Introduction
Influenza A viruses are important respiratory pathogens that
cause annual epidemics and occasional pandemics. The 2009
H1N1 pandemic (H1N1pdm) is a reminder of the need to develop
and improve tools for rapid identification of emerging and novel
viruses. Influenza A viruses consist of a segmented negative sense
RNA genome which is prone to acquisition of point mutations and
gene reassortment [1]. The two major surface antigens, the
hemagglutinin (HA) and neuraminidase (NA) glycoproteins, are
coded by their respective HA and NA genes. The remaining six
‘‘core’’ genes (PB1, PB2, PA, NP, M, and NS) encode eight to nine
viral proteins (PB1, PB1-F2, PB2, PA, NP, M1, M2, NS1, and
NS2) [2,3].
Influenza A virus evolution is considered to be predominantly
driven by host-mediated selective pressure that leads to amino acid
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as antigenic drift [4,5]. Another mechanism of influenza virus
evolution, antigenic shift, which occurs at a lower frequency,
involves the replacement of HA and/or NA with new antigenic
virus subtypes that have not circulated in humans viruses for a long
time [6].
Inter-subtype reassortment is rare, whereas intra-subtype
reassortment occurs more often among distinct co-circulating
lineages of the same influenza A virus subtype [7,8]. In particular,
intra-subtype reassortment events have been reported to result in
the acquisition of drug resistance and may facilitate the spread of
drug resistant viruses [9,10–12]. In addition to natural reassort-
ment, live attenuated vaccines are generated to include HA and
NA genes from epidemiologically relevant strains and the ‘‘core
genes’’ from the master donor viruses (e.g. cold adapted A/
California/7/09(H1N1pdm) x A/Ann Arbor/6/60(H2N2)) [13].
In April 2009, a previously unseen virus emerged and rapidly
spread globally leading to the first influenza pandemic of the 21
st
century [14]. The H1N1pdm virus has a complex genome
composition, with genes originating from swine, human and avian
influenza A viruses. Complete genome sequencing and phyloge-
netic analysis demonstrated that the virus had genes related to
North American triple reassortant and Eurasian swine viruses [15–
17], including the M gene of adamantane-resistant Eurasian
avian-like swine viruses [16].
The continuous evolution of influenza genomes together with
reassortment events pose challenges to the effective monitoring of
influenza viruses in circulation. Current methods of laboratory
influenza surveillance are primarily based on hemagglutinin
inhibition (HI) and other assays utilizing the antibody recognition
of viral antigens [18,19]; conventional or real-time RT-PCR
methods [20–24]; and sequencing coupled with phylogenetic
analysis (e.g. as in [16]). These methods, though commonly used,
each has certain unique advantages but also some limitations. For
example, some are designed for rapid testing, without greater
attention given to the degree of sensitivity or specificity; others
allow virus typing but do not provide details on subtypes; and
some of the more sensitive and accurate methods may not but
suited high throughput testing …etc.
Oftentimes, there is a strong correlation between the sequences
of the ‘‘core’’ genes and the ‘‘surface’’ HA and NA genes of
influenza A viruses [25]. Thus, in the absence of a reassortment,
identification of ‘‘core’’ genes can be used to infer the viral HA and
NA subtypes. Noteworthy is the fact that reassortment is rather
common among porcine viruses (e.g., H1N2, H3N1, H1N1, and
H3N2) [26], thus making it more challenging to infer their
subtypes based on core gene constellation.
The RT-PCR/ESI-MS assay was previously introduced for
detection and characterization of influenza viruses [25,27,28]. The
BC signatures of each amplicon are then determined using
automated ESI-MS signal acquisition and spectral analysis.
Identification of each influenza A virus is based on the
summation of BC signatures obtained from the six target genes
(PB1, NP, M1, PA, NS1, and NS2). This combination of BC
signatures is referred to as ‘‘genomic print’’ throughout the
manuscript, and is used for comparison to previously known
viruses with BC signatures and/or genomic prints in a reference
database. The viruses are identified by the virus(es) in the database
with the closest match to their genomic prints/or BC signatures.
For instance, if a virus has a genomic print identical or similar to a
known reference virus, it will be identified as such. On the other
hand, if a virus has a genomic print that is not identical or similar
to a single reference virus (e.g. different genes from different
subtypes or different hosts); it will be identified with more than one
virus (e.g. in the case of a reassortant). Finally, if the virus has no
known close matches to its BC signatures in the database, it will be
identified as ‘‘unknown’’.
In the present study, we focused on the influenza RT-PCR/
ESI-MS assay’s ability to identify influenza A viruses affecting
humans. Based on our previous experience with the assay using
seasonal influenza viruses, and its reported performance in analysis
of influenza A(H3N2) [25], the main goals of this study were to
investigate: (A) whether the RT-PCR/ESI-MS assay can be
applied for identification of the H1N1pdm viruses; (B) whether
this method could be helpful in the analysis of A(H3N2) virus
lineages from the 2006-07 to 2008-09 seasons; (C) whether the
assay could identify and distinguish between the major lineages of
seasonal H1N1 viruses (2B and 2C clades), including the dual
oseltamivir and adamantane-resistant viruses; and lastly (D)
whether wild type viruses could be readily distinguished from
the live attenuated vaccines (LAIV) using this assay.
Our efforts show that that the RT-PCR/ESI-MS assay provides
a broad range, high throughput identification tool that could be
used for influenza virus surveillance purposes. It can successfully
detect novel viruses, including those arising from the reassortment
of ‘core’ genes, and the assay has the ability to differentiate among
genetic groups (lineages or clades) within the same virus subtype.
Results
Identification of the H1N1pdm viruses using
RT-PCR/ESI-MS
The RT-PCR/ESI-MS assay was applied to test the ‘‘un-
subtypable’’ clinical specimen of the first US H1N1pdm virus, A/
California/4/2009, at the Naval Health Research Center
(NHRC), in San Diego CA, USA [29]. The results (Figure 1)
showed no match to any known genomic prints in the database,
but clearly indicated the presence of an unusual influenza A virus,
showing BC signatures of individual genes that were similar to
those from viruses of swine, human, and avian origins. It should be
noted that although this initial identification showed deficiencies in
accurately determining the origin of each gene of this complex
reassortant virus, results such as these would alert the investigator
of the need for further analysis through the use of traditional
methods. After the complete genome sequence and phylogenetic
analysis of the A/California/4/2009 were examined [16], the BC
signatures of this virus were added to the database. Its genomic
print was easily distinguishable from those of seasonal H1N1 and
H3N2 and other influenza A viruses (Figure 2), and became the
reference for the identification of subsequent H1N1pdm viruses. It
is also important to note that the BC signatures of the pandemic
virus are readily discernible from those of swine triple reassortant
viruses that have previously caused infections in humans [15]. The
criterion used for future identification of the H1N1pdm viruses
was based on the detection of BC signatures identical to those of
A/California/04/2009 in at least five of the six targets in the
‘‘core’’ genes. The original screen shot obtained directly from the
T5000 instrument (Figure 1) is presented as Figure S1.
Use of RT-PCR/ESI-MS for high throughput screening and
monitoring of the H1N1pdm viruses for genomic
variations
To further assess the ability of the RT-PCR/ESI-MS assay to
accurately identify the pandemic viruses and determine its sensitivity
and specificity, we tested 401 specimens previously characterized
using the CDC rRT-PCR assay [http://www.who.int/csr/
resources/publications/swineflu/CDCrealtimeRTPCRprotocol_
20090428.pdf]. These samples were collected during the early
RT-PCR/ESI-MS for Influenza
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hundred forty-four (144) of them were identified as H1N1pdm
using the RT-PCR/ESI-MS; while based on CDC-rRT-PCR
assay results, 152 of them were positive for the H1N1pdm. One
sample tested positive in the RT-PCR-ESI-MS but negative in the
rRT-PCR. This corresponds to an overall sensitivity of ,94.1%
(Table 1). Among these positive samples, 120 were from residual
RNA from clinical specimens and the remaining were grown
viruses. Of the 249 specimens identified as negative rRT-PCR,
248 also tested negative by RT-PCR/ESI-MS, corresponding to a
specificity of 99.59% (Table 1). Four of the 9 samples that were
identified as positive based on the rRT-PCR but negative by the
RT-PCR/ESI-MS matched the reference H1N1pdm virus
signatures in less than five targets, which is below the acceptance
criteria, set in the system. The remaining five samples had less than
adequate volume of RNA material. Of note, after the sensitivity
and specificity analyses were performed on the early specimens
and more samples became available, another set of 133 left over
RNAs of confirmed cases of H1N1pdm by the rRT-PCR
(including 89 from clinical specimens) were analyzed in the RT-
PCR/ESI-MS assay and were confirmed as such. This brought the
final total number of H1N1pdm viruses identified by this assay to
277, with 209 being from original clinical specimen.
As shown in Figure 2, BC signatures of the H1N1pdm viruses
were clearly distinguishable from those of seasonal H1N1, H3N2,
as well as from swine triple reassortant H1N1 viruses. BC
signature patterns were color-coded for clarity. The genomic
prints of most samples tested were identical and consistent with
that of the reference virus A/California/04/2009. However,
approximately 10% of the samples showed a single nucleotide
polymorphism (SNP) in the PA gene at nucleotide 618 (A to G
mutation) (Figure 2). The base counts results obtained for each
amplicon, determined by the RT-PCR/ESI-MS, were compared
and found consistent with the genome sequencing data available
for a subset of the viruses analyzed here [16].
Distinction between the BC signatures of the H1N1pdm virus
from those of other stable influenza A subtype viruses collected
between 2006-07 and 2008-09 (Table S1), is further illustrated in
Figure 3. Details on the spatial representation of the BC signature
data is described elsewhere [25]. Superposition of BC from the
H1N1pdm viruses showed that for five of the six target regions, the
H1N1pdm signatures are unique. The PB1 signatures of
H1N1pdm and human H3N2 viruses overlapped as expected
based on phylogenetic analysis of this gene segment [16].
Results from the limits of the detection studies of the H1N1pdm
virus using the RT-PCR/ESI-MS assay showed that the lowest
detectable concentrations of the virus varied from 7.0610
1
TCID50/ml to 2.11610
2 TCID50/ml, depending on the matrix
(nasal swab or nasal wash) used for sample dilution (Table S2).
Analysis of sensitivity of the assay based on viral genome copy
numbers revealed that the LoD of the assay was 31 and 62 genome
copies, from the nasal swab and nasal wash, respectively, using the
Ambion MagMaxH Viral RNA Isolation kit. The same analysis
using the Qiagen QIAampH MinElute Virus Spin kit demonstrat-
ed that the assay’s LoD of was 125 and 62 viral genome copy
numbers, from the nasal swab and nasal wash, respectively. Of
note, the limit of detection here (the numbers) is considered only if
all primers generated PCR products and BC signatures in the
assay (Figure S2).
Analysis of seasonal A(H3N2) viruses circulating from
2006-07 to 2008-09 seasons using RT-PCR/ESI-MS
During the 2006-07 season, new antigenic variants of A(H3N2)
viruses emerged and were different from the vaccine strain A/
Wisconsin/67/2005. In addition, distinct patterns of adamantane
susceptibility were observed among the co-circulating genetic
Figure 1. RT-PCR/ESI-MS identified initial H1N1pdm strain as unusual virus with genome components of swine, human, and avian
origin. RNA from clinical specimens was prepared from one of the first cases of the 2009 pandemic and tested using the RT-PCR/ESI-MS assay. BC
signatures did not match any of the known reference genomic signatures in the database. The signatures indicated a close relationship to swine,
human and avian sequences. The gene segments targeted were PB1 (VIR2798), NP (VIR1266), M1 (1279), PA (1287), NS1 (2775), and NS2 (2777). The
base counts determined for each target are highlighted in green; below them are the number of viral RNA copies and the SNP variations from the
matching strain, respectively.
a VIR2798= PB1; VIR1266= NP; 1279= M1; 1287= PA; 2775= NS1; 2777= NS2;
b The tested sample had 4 different
close matches in the reference database, depending on the six targets;
c The closest matching virus, from reference the database, to the sample
tested;
d The numerators refer to # of targets identified. The denominators refer to the number of entries (# of genes) from the different viruses
represented with BC signatures in the database;
e The sample tested had matches to viruses from swine, human, and avian, but identification of
origin was not correct for all genes (e.g. the NP had a closest match in a human H1N1 virus, while genome sequencing revealed the virus has NP
related to North American triple reassortant swine H1N1).
doi:10.1371/journal.pone.0013293.g001
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usefulness of the RT-PCR/ESI-MS method in screening a large
number of H3N2 viruses in order to identify major genetic
lineages co-circulating in different parts of the world. Such
information could be useful in making decisions and recommen-
dations on new vaccine strain selection and M2 antiviral drug
(adamantanes) usage. To this end, 76 viruses collected from
various geographic regions in 2006–2007 were analyzed. Twenty
unique genomic prints were identified. The most dominant
genomic print among the adamantane-resistant viruses (AADFAA)
was shared with H3N2 viruses that circulated in prior seasons (N-
lineage) [25]. Table 2 represents the identified genomic prints. In
parallel to the RT-PCR/ESI-MS, full genome sequencing and
phylogenetic analyses were performed on 65 of the 76 viruses [12].
Comparison of results from both approaches showed that the
genomic prints identified by the RT-PCR/ESI-MS belong mainly
to one of the four major genetic groups determined by
phylogenetic analysis: 1) two adamantane-sensitive groups, A/
Nepal/921/2006-like and A/Brisbane/09/2006-like, and 2) two
adamantane-resistant groups, A/Nepal/921/2006-N144D-like
and A/Brisbane/10/2007-like (Table 2). Two genomic prints
were identified for 2 viruses belonging to the N-lineage; while the
three remaining genomic prints were unique to three viruses which
circulated prior to the N-lineage appearance.
RT-PCR/ESI-MS analysis of 95 H3N2 viruses, collected during
2007-08 and 2008-09 influenza seasons (57 and 38, respectively,
Table S1), revealed that all shared the genomic print of the reference
virus A/Brisbane/10/2007 and no evidence of major genetic
changes were detected based on the ‘‘core’’ gene segments analyzed.
Together, these findings show that the assay could be used as a
primary screening tool to identify major genetic groups based on
their genomic prints. This can help in reducing the redundancy of
sequencing identical viruses by identifying those with unique
genetic features and not duplicating the same sequences.
Identification of genetic groups of co-circulating
seasonal A(H1N1) viruses
The emergence and co-circulation of seasonal pre-pandemic
H1N1 viruses resistant to oseltamivir and/or adamantanes has
been a serious public health concern. Recently, an increasing
number of dually resistant viruses that emerged from reassortment
between two genetic lineages (clades 2B and 2C) of seasonal H1N1
viruses was reported [30,31,32]. We assessed the ability of the RT-
PCR/ESI-MS assay to identify such reassortants.
First, 14 seasonal H1N1 samples with known full genome
phylogenies were tested to identify the clades to which they
belonged based on the RT-PCR/ESI-MS. This assay successfully
identified viruses from clades 2B (n=9) and 2C (n=5) (Figure 4).
The genomic prints of these two seasonal H1N1 groups differed
from each other mainly by the PB1, PA, and M1 genes, with M1
gene providing the highest dissimilarity resolution.
Figure 2. The genomic print of H1N1 pdm viruses is highly conserved and distinct from other influenza viruses. Thirteen (13) seasonal
H1N1 and H3N2 viruses from various seasons (top half); 12 samples from the H1N1pdm viruses (including the two viruses of the first two cases of the
2009 pandemic, referred to as NHRC1 and 2) (bottom half in yellow highlight); and a North American swine of H1N1 subtype were analyzed. All 2009
H1N1 pdm viruses have the same genomic print. BC signatures of five of the six targets in the H1N1pdm virus (NP, M1, PA, NS1, and NS2) were
different from the other subtypes. The BC signature determined for the PB1 (A39, G32, C24, T33) was identical to some human H3N2 viruses, as
expected. The H1N1pdm viruses were also distinguishable from the triple reassortant swine H1N1 at all six targets (compare yellow and purple
signature). Differences in color patterns within the same subtype either reflects different genetic groups (H3N2 and H1N1), or a single nucleotide
polymorphism (2009 H1N1 pdm). The numbers preceded by letters in each box correspond to the base counts (number A, G, C, and T) determined
from the amplicons of the respective target genes.
doi:10.1371/journal.pone.0013293.g002
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phylogenies were tested. Fourteen had genomic prints identical to
that of the clade 2B reference virus, A/South Dakota/06/2007,
with two viruses each having one SNP in the PB1 amplicon, one
with a SNP in the NP gene target, and one that failed to amplify
using the PB1 primers (Figure 5). Seven viruses had hybrid BC
signatures from both clades 2B and 2C: the PB1, NP, PA, NS1,
and N2 BC signatures belonged to clade 2B, while the M1 BC
signature was clearly that of clade 2C, suggesting acquisition of the
clade 2C M segment by viruses from clade 2B by reassortment.
The data were similar to the findings of the phylogenetic analysis:
these viruses with hybrid BC signatures matched the genomic
print of A/Texas/57/2009, a known reassortant virus with all
genes from clade 2B, except the M gene, which is acquired by
reassortment from a clade 2C virus [32]. The remaining two
viruses (Figure 5, samples 1 and 2) contained SNPs in their M1
genes and thus, the identification of the clades to which they
belong could not be confirmed.
Noteworthy, the genomic prints of seasonal H1N1 viruses
including the identified reassortants were distinguishable from
other influenza A viruses.
Distinction between live attenuated influenza vaccine
(LAIV) and the wild type 2009 H1N1 pdm viruses using
the RT-PCR/ESI-MS
Since live attenuated vaccines contain the ‘core genes’ of the
master donor virus A/Ann Arbor/6/60 (H2N2), it was essential to
investigate if its genomic print significantly differs from those of
wild type viruses in circulation. Indeed, the identified genomic
print of the H1N1pdm LAIV was clearly distinguishable from that
of wild type 2009 H1N1 pdm virus, seasonal H1N1, seasonal
H3N2 viruses and other viruses of animal origin. Figure S3
represents results of RT-PCR/ESI-MS analysis of an H1N1pdm
LAIV case (ID: 2010703400).
The results indicate that the assay facilitates distinction between
the wild type 2009 H1N1 pdm and its cold adapted vaccine strain.
Discussion
Pandemic influenza viruses have caused morbidity and
mortality in humans and have negatively impacted the world’s
economy [33]. The availability of tools that allow rapid
identification of novel viruses during routine surveillance is critical
in pandemic preparedness and response management.
The present study describes the use of the RT-PCR/ESI-MS
assay at the Naval Health Research Center (NHRC) to identify the
‘‘unsubtypable’’ influenza A virus present in the specimen from
one of the first cases of H1N1pdm [17,29]. The results generated
at NHRC using the standard RT-PCR/ESI-MS Influenza assay
indicated that the virus was different from the currently known
circulating human influenza viruses. This new virus had distinct
BC signatures that suggested genome contributions from swine,
human and avian influenza A viruses. Nevertheless, its accurate
identification as a swine-origin reassortment of H1N1 subtype was
made only after genome sequence and phylogenetic analyses were
performed at CDC and other laboratories [16,34]. This same
Influenza RT-PCR/ESI-MS assay has been used at the CDC
since 2007 to test seasonal viruses, and was also independently
used for identification of the H1N1pdm viruses soon after
characterization of the first isolates.
The RT-PCR/ESI-MS assay, despite being capable of
identifying novel and emerging viruses, is not an alternative to
conventional virus characterization methods such as rRT-PCR
and complete genome sequencing complemented with phyloge-
netic analysis. However, the RT-PCR/ESI-MS occupies its own
niche by determining the genomic prints of ‘‘core’’ genes of viruses
analyzed and rapidly providing a snap shot of their genome
composition on the basis of previously characterized standards.
This assay allows testing of ,300 samples in 24 h, with first results
obtained within 6 h [28]. In its current form, the assay is semi-
automated, with sample preparation and amplifications performed
outside the system, whilst all post-PCR amplification steps are
automated in the T5000 biosensor. Recently, numerous high
throughput sequencing technologies have been developed to allow
rapid and cost-effective ways to obtain genome-wide information
[35–37]. However, it is important to underline that choosing
which of these methods to use is often driven by a combination of
a number of factors including: sensitivity, specificity, fitness-for-
purpose, technical ease, and time and cost of effectiveness. The
influenza RT-PCR/ESI-MS assay lends itself as a complementing
tool to the array of assays currently in use, especially in the field of
surveillance; and like any other technology, it has its own
advantages and limitations. For example, this assay has some
similarities with Sequenom MassARRAY iPLEX genotyping
platform [38]. Both are based on measurement of masses of
nucleotides from an amplified target. However, they differ in that
the latter is aimed determining a single SNP per amplicon. This
assay allows multiplexing of up to 40 different SNPs per run, if
properly designed [39]. The RT-PCR/ESI-MS is not limited to
analysis of one SNP in an amplicon; it rather determines the base
counts of the amplicon in a form of a signature. These signatures
are then used for sample identification. Neither of these two
technologies generates sequences as do other NGS platforms such
as 454 GS-FLX system, Illumina, and Sequencing by Oligonu-
Table 1. Sensitivity and specificity of the RT-PCR/ESI-MS assay
in detecting the 2009 H1N1pdm in comparison to the CDC
rRT-PCR assay.
CDC Real time RT-PCR Assay
Positive Negative Total
Positive 143 1 144
T5000 Negative 9 248 257
Total 152 249 401
Sensitivity 94.1
Specificity 99.6
Pos Pred Value 99.3
Neg Pred Value 96.5
During the period from April to June, a total of 401 RNA samples randomly
collected during the early stages of the pandemic were tested in the assay. One
hundred forty-four (144) of them were identified as H1N1pdm using the RT-
PCR/ESI-MS; while based on CDC-rRT-PCR assay results, 152 of them were
positive for the H1N1pdm. This corresponds to a sensitivity of 94.07%. Among
these positive samples, 120 were from residual RNA from clinical specimens and
the remaining were grown viruses. Of the 249 specimens identified as negative
rRT-PCR, 248 also tested negative by RT-PCR/ESI-MS, corresponding to a
specificity of 99.59%. Four of the 9 samples that were identified as positive
based on the rRT-PCR but negative by the RT-PCR/ESI-MS matched the
reference H1N1pdm virus signatures in less than five targets, which is below the
acceptance criteria, set in the system. The remaining five samples had less than
adequate volume of RNA material. Of note, after the sensitivity and specificity
analyses were performed, and more samples became available, another set of
133 left over RNAs of confirmed cases of H1N1pdm (including 89 from clinical
specimens) were analyzed in the RT-PCR/ESI-MS assay and were confirmed as
such. This brought the final total of H1N1pdm viruses identified by this assay to
277, with 209 being from original clinical specimen.
doi:10.1371/journal.pone.0013293.t001
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GS-FLX system specifications states that it can sequence an
average of 100 million DNA bases in a 7.5-h run, with an average
read lengths of 250 bases (http://www.454.com). However, it does
not allow the in-depth coverage and massive parallel sequencing
provided by Illumina (http://www.illumina.com) or SOLiDTM
(http://solid.appliedbiosystems.com) systems, respectively. Of note
the latter two technologies have the limitation of providing only
short sequence reads of 35–50 bases and a complete run takes ,3–
5 days [39,40]. All of the above mentioned technologies are of
high throughput nature, and in some applications two or more of
them were combined for more efficiency and accuracy [39].
The RT-PCR/ESI-MS is based on the use of neural network
analysis to compare newly generated BC signatures to those of
viruses already in a reference database. It is important to highlight
that final identification of any virus (e.g. strain name, subtype,
host, etc…) depends on the information contained in this reference
database. The assay generates BC signatures for the sample tested;
however, the other virus identifiers are determined based on
comparison to virus sequences (generated outside the RT-PCR/
ESI-MS assay) and other virus attributes (such as host, clade,
etc…), in the database. It is also important to note that for the RT-
PCR/ESI-MS assay to provide the most accurate and up-to-date
results, the reference database must be continuously updated with
new virus sequences and relevant strain information. The present
study has contributed to the enrichment of the database with the
addition of the new viruses’ BC signatures and genomic prints.
Noteworthy, neural network-based analyses, such as the one
employed in the RT-PCR/ESI-MS, are often biased by their
database content. For instance the number of genomic prints and/
or BC signatures as well as the source of these signatures, how well
up-to-date are the references in the databases…etc, and gene
sequencing combined phylogenetic analyses still provides the most
complete answer among currently available influenza surveillance
tools.
Given the high throughput nature of the RT-PCR/ESI-MS
assay and its ability to differentiate between H1N1pdm and
seasonal viruses, it has become a useful tool for monitoring
genome reassortments in these viruses.
The Influenza kit in its current format is not a diagnostic tool;
however there are ongoing efforts to explore the usefulness of the
assay for clinical applications. Primers for amplification of the two
genes encoding the surface antigens (HA and NA) are not included
in the current kit. The HA and NA subtypes are only inferred from
the results of the ‘‘core’’ genes analysis. Such conclusions may be
accurate only with stable subtypes of influenza that are not
Figure 3. Spatial representation of BC signatures covered by the six primer pairs for Influenza A viruses characterization. Black
numerals refer to the individual primer pair numbers, and are followed by the designation of the segment from which they stem (between
parentheses). For each primer pair, each sphere represents one strain of influenza circulating within the seasons 2007–2009, and is color coded by
host and subtype: 1) light blue, human H1N1; 2) dark blue, swine triple reassortant H1N1; 3) light green, human H3N2; 4) dark green, swine triple
reassortant H3N2; 5) and red, H1N1pdm. For clarity, ellipses regroup the most common subtypes in circulation. Each isolate is mapped in a three-
dimensional space according to its amplicon BC signature using the designated primer pair.
doi:10.1371/journal.pone.0013293.g003
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subtypes based on the genomic prints, limited to ‘core’ genes,
should be done with great caution. Notable to the current
Influenza kit is its failure to include the influenza A PB2 gene
segment. As such, the current assay would not identify an
emerging virus that contains a PB2 gene acquired through
Table 2. Identification of unique genomic prints in H3N2 viruses circulating during the 2006-07 influenza season and their
correlation with genome sequencing and M2 susceptibility data.
Strain Designation Genomic prints{ Genome sequencing lineages M2- blockers susceptibility*
A/Wisconsin/02/2007 AEEFAA B- (Nepal/921/2006-like) S
A/Nepal/921/2006 CEEFAA B- (Nepal/921/2006-like) S
A/Bangladesh/1999/2006 GEBFAA B- (Nepal/921/2006-like) S
A/Indiana/03/2007 CDEFAA B- (Nepal/921/2006-like) S
A/Lyon/10/2006 CEAFAA B- (Nepal/921/2006-like) S
A/Korea/7212/2007 AADFAA A- (Nepal/921/2006-N144D-like) R
A/Korea/7210/2007 AABFAA A- (Nepal/921/2006-N144D-like) R
A/Japan/7288/2007 CADFAA A- (Nepal/921/2006-N144D-like) R
A/Incheon/701/2006 ACDFAA A- (Nepal/921/2006-N144D-like) R
A/Wisconsin/43/2006 AEJBAA C-(Brisbane/09/2006-like) S
A/Bordeaux/1276/2006 ECJBAA C-(Brisbane/09/2006-like) S
A/Lyon/CHU/52.58/2006 CCJBAA C-(Brisbane/09/2006-like) S
A/Daejeon/690/2006 ACJFAA C-(Brisbane/09/2006-like) S
A/New Mexico/02/2007 CCLFAA D-(Brisbane/10/2007-like) R
A/Idaho/03/2007 CCDFAA D-(Brisbane/10/2007-like) R
A/Kentucky/3e/2006 CEDBAA N-lineage R
A/Venezuela/6971e/2005 ACBBAA N-lineage R
A/Omsk/32/2004
{ AABNAA Pre-N-lineage R
A/Fujian/411/2002
{ HADFAA Pre-N-lineage S
A/Wuhan/396/2001
{ AADBAA Pre-N-lineage R
The six letters in the genomic prints for each virus refer to different BC signatures determined based on the six targets. (e.g. A/Wisconsin/02/2007 has BC signature for
PB1 that was designated A, BC signatures at NP and M1 were each designated E, its BC signature at PA was named F, and the BC signatures at NS1, and NS2, were each
designated A).
{Viruses were collected prior to 2005 and were used as reference viruses.
*S: sensitive; R: resistant.
doi:10.1371/journal.pone.0013293.t002
Figure 4. RT-PCR/ESI-MS assay allows differentiation between the two major seasonal H1N1virus clades 2B and 2C. Fourteen H1N1
viruses with previously known clades (based on phylogenetic data) were blindly tested and the results were analyzed against data base reference
viruses: A/South Dakota/06/2007 and A/Colorado/UR06-0053/2007, of clades 2B and 2C, respectively. Nine of the viruses were identified as clade 2B
and the remaining five as clade 2C, mainly based on the combination of BC signatures of PB1, M1, and PA (highlighted in yellow). The remaining 3
targets (NP, NS1, and NS2) had identical BC signatures in both groups of viruses (highlighted in light green). One or two SNPs were also detected in
two viruses (light blue) but had no effect on clade identification. *The numbers preceded by letters in each box correspond to the base counts
(number A, G, C, and T) determined from the amplicons of the respective target genes.
doi:10.1371/journal.pone.0013293.g004
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greatly improve the assay, even if this would require designing
assays that are subtype specific and/or are aimed at addressing
specific issues, such as monitoring the possibility of reassortment
between the pandemic viruses and H5N1 viruses.
Of importance is the fact that the RT-PCR/ESI-MS can be
used for testing clinical specimens directly and does not require
virus culturing; and therefore can be time and cost effective.
The RT-PCR/ESI-MS assay demonstrated its usefulness in
performing initial screening of a large number of H3N2 viruses
and grouping them in accordance with their molecular signatures
thus saving time and resources.
The RT-PCR/ESI-MS assay also demonstrated its ability to
identify and distinguish seasonal H1N1 viruses of various genetic
groups (clades). This information could be valuable in monitoring
for reassortment between viruses from different genetic lineages
within the same subtype. It is important to note that such intra-
subtype reassortments have resulted in the emergence and limited
spread of viruses dually resistant to both the NA inhibitor
oseltamivir and the adamantanes [30,31]. The possibility of
reassortment between oseltamivir-resistant H1N1 seasonal and
H1N1pdm viruses is an obvious concern.
Our data demonstrate the ability of the RT-PCR/ESI-MS to
detect and identify dually resistant viruses of seasonal H1N1 that
appeared as a result of reassortment between clade 2B (oseltamivir
resistant) and clade 2C (adamantane resistant) lineages of seasonal
H1N1 viruses. It is important to emphasize, however, that in some
rare cases, occurrence of new mutations in the region targeted for
M1 primers could change the BC signature and complicate
discrimination between clades 2C and 2B.
In addition to monitoring the pandemic and seasonal influenza
viruses, the RT-PCR/ESI-MS assay could be useful in identifying
and differentiating LAIV from infections with wild type viruses.
Furthermore, the assay has proven its capacity to detect mixed
infections of different types/subtypes of viruses ([25], Deyde et al.,
2009 unpublished data).
Our data demonstrate that the RT-PCR/ESI-MS assay is a
valuable tool for detecting emerging viruses, for large scale
screening for genome variants, and in monitoring for reassortment
events with the caveat that additional targets (to include all eight
influenza segments) should be added to the assay. Finally, the assay
could be greatly improved by using two primer sets for each
segment. This would reduce the influence of SNPs occurring in
one of the targets on the same segment, and strengthen the
identification capability of the influenza RT-PCR/ESI-MS assay.
Materials and Methods
Viruses
Clinical specimens (throat swabs, nasal swabs and washes,
nasopharyngeal swabs, blood, sputum) and viral isolates submitted
to CDC as part of the Global Influenza Surveillance Network
activities from various regions of the world were used for RNA
extraction and randomly selected for analysis using RT-PCR/ESI-
Figure 5. Detection of intra-subtype reassortment among seasonal H1N1 viruses using the RT-PCR/ESI-MS assy. A set of 23 viruses
with unusual drug resistance profiles (resistant to both oseltamivir and the adamantanes) were analyzed; fourteen (14) of them showed genomic
prints identical to the prototype clade 2B virus, A/South Dakota/06/2007 (green highlight), based on all six targets, with the exception of three viruses
that had single SNPs each in the PB1 amplicon (two) and the NP (one) (light purple). Sample 23 did not amplify with the PB1 target. Seven viruses had
five BC signatures (from PB1, NP, PA, NS1, and NS2) matching the clade 2B virus, while their M1 BC signature was typical of clade 2C virus, A/
Colorado/UR06-0053/2007 (light yellow). Two viruses had genomic prints uncharacteristic of either clade 2B or clade 2C (samples 1 and 2). The
numbers preceded by letters in each box correspond to the base counts (number A, G, C, and T) determined from the amplicons of the respective
target genes.
doi:10.1371/journal.pone.0013293.g005
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seasonal influenza H1N1 (n=302), H3N2 (n=171), as well as
triple reassortant swine viruses (n= 7) isolated from humans.
Reference viruses with full genome sequences available in the
public domain were used for RT-PCR/ESI-MS assay results
comparison and identification; and they included: A/South
Dakota/06/2007 (seasonal H1N1, clade 2B), A/Colorado/
UR06-0053/2007 (seasonal H1N1, clade 2C), A/Texas/57/
2009 (seasonal H1N1-clades 2B and 2C reassortant virus), A/
Brisbane/10/2007 (H3N2), A/Ohio/01/2007 (triple reassortant
swine H1N1), A/Michigan/09/2007 (triple reassortant swine
H1N2), and A/California/04/2009 (H1N1pdm virus). B/Flor-
ida/04/2006 was also used as a reference virus in case type B
viruses were present among the samples tested, a consequence of
virus mistyping or mixture. A/Ann Arbor/6/60 (H2N2) and B/
Ann Arbor/1/66 viruses were used as reference viruses for LAIV
strains.
Genomic prints of these viruses were determined based on their
known genetic sequences and were used as references in the
database.
Ethics Statement
The Global Influenza Surveillance Network is public health
surveillance, not human subjects’ research. Therefore, evaluation
of left-over surveillance specimens did not require IRB review or
informed consent.
Viral RNA isolation
RNAs were extracted using either MagNA Pure Compact RNA
isolation kit, MagNA Pure LC total nucleic acid kit or MagNA
Pure LC 2.0 RNA isolation kit (Roche, Indianapolis, IN). The
viruses tested were initially characterized by rRT-PCR and/or
hemagglutination inhibition (HI) tests at the Influenza Division,
CDC.
RT-PCR/ESI-MS assay
In brief, based upon analysis of multiple influenza sequence
alignments, pan-influenza virus RT-PCR primer sets were
developed to generate information-rich sequences as previously
detailed [25]. An influenza assay (Cat #03N39-01, Abbott
Molecular, Des Plaines, IL) was then designed, consisting of eight
primer pairs, including one pan-influenza primer pair targeting
the PB1 segment, five pan-influenza A primer pairs targeting NP,
M1, PA and NS (NS1 and NS2 genes), and two pan-influenza B
primer pairs targeting NP and PB2 gene segments. All primers
used in this study had a thymine nucleotide at the 59-end to
minimize addition of non-templated adenosines during amplifica-
tion using Taq polymerase [41]. The sensitivity of each RT-PCR
primer pair was determined using known quantities of a synthetic
calibrant RNA template as described previously [42].
One-step RT-PCR was performed as previously described [25].
Following amplification and product purification, molecular
masses and base counts of amplicons were determined, using the
T5000 platform, as previously described in detail [25,42–45].
Semi-quantitative results of viral RNA genome copy numbers
were obtained by comparing the peak heights with an internal
PCR calibration standard present in every PCR well at 100
molecules [43].
Limit of detection (LoD) studies on the H1N1pdm
specimens
To determine the overall limit of detection of the RT-PCR/
ESI-MS assay from nucleic acid extraction to data analysis, two
different extraction methods with spikes of the H1N1pdm virus,
A/California/04/2009, in two different matrices, nasal swab and
nasal wash, were used to establish the LoD. Ten serial dilutions of
the pandemic strain were prepared in the two matrices. RNA from
each diluted sample was independently extracted using the
Ambion MagMaxH Viral RNA Isolation kit (Applied Biosys-
tems/Ambion, Austin, TX) and using the Qiagen QIAampH
MinElute Virus Spin kit (Valencia, CA). Extracted RNA was
added to the RT-PCR/ESI-MS assay kit and the plates were
thermocycled on the Eppendorf Master cycler (Hauppauge, NY).
The amplicons were then tested on the T5000 machine (Ibis/
Abbott, Des Plaines, IL). The LoD was calculated to determine the
lowest detectable concentration range of influenza virus at which
$95% of all replicates across extraction methods tested positive. A
positive result was defined as the detection of at least five of the six
amplicons whose BC signatures match the H1N1pdm strain,
resulting in the T5000’s call of the pandemic virus.
Supporting Information
Figure S1 RT-PCR/ESI-MS identified initial H1N1pdm strain
as unusual virus with genome components of swine, human, and
avian origin.
Found at: doi:10.1371/journal.pone.0013293.s001 (2.09 MB TIF)
Figure S2 Limit of detection (LoD) studies on the H1N1pdm
specimens.
Found at: doi:10.1371/journal.pone.0013293.s002 (0.72 MB TIF)
Figure S3 Results of RT-PCR/ESI-MS analysis of an
H1N1pdm LAIV case.
Found at: doi:10.1371/journal.pone.0013293.s003 (0.40 MB TIF)
Table S1 Distribution of influenza A viruses analyzed in this
study based on subtype and collection period.
Found at: doi:10.1371/journal.pone.0013293.s004 (0.03 MB
DOC)
Table S2 Analytical Limits of Detection (LoD).To assess and
determine the limit of the detection of the RT-PCR/ESI-MS
assay, analytical limits of detection studies (see Materials and
Methods) were performed using the 2009 H1N1pdm strain. The
results showed that the lowest detectable concentrations of
influenza virus varied from 7.06101 TCID50/ml to 2.116102
TCID50/ml, depending on the matrix used: nasal swab or nasal
wash (Table S2). It should be noted that these viral copy numbers
determined by TCID50s may over look presence of defective
interfering (DI) particles and therefore the lowest detectable
number of molecules could be higher. Analysis of sensitivity of the
assay based on viral copy numbers revealed that the LoD of the
assay was 31 and 62 genome copies, from the nasal swab and nasal
wash, respectively, using the Ambion MagMaxHViral RNA
Isolation kit. The same analysis using the Qiagen QIAampH
MinElute Virus Spin kit showed the LoD of the assay was 125 and
62 viral copy numbers, from the from the nasal swab and nasal
wash, respectively. Of note, the limit of detection here (the
numbers) is considered only if all primers generated PCR products
and BC signatures in the assay. Reference: Teresa Zembower,
Varough Deyde, Larisa Gubareva, Alexander Klimov, Sudhir
Penugonda, Kevin Kunstman, Maureen Bolon, David Dittman,
Lawrence Blyn, David Ecker, Steven Wolinsky, Rangarajan
Sampath. PCR/ESI-MS Approach for High-Throughput Identi-
fication of 2009 Pandemic Influenza A Viruses. 49th Interscience
Conference on Antimicrobial Agents and Chemotherapy
(ICAAC), San Francisco, California, September 12 - 15, 2009
Found at: doi:10.1371/journal.pone.0013293.s005 (0.04 MB
DOC)
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